Stay updated on Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial page.

Latest updates to the Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded a Locations section listing state sites (Arizona, California, Colorado, Massachusetts, New Jersey, Pennsylvania, Washington) and updated the revision to v3.3.3. Removed the HHS Vulnerability Disclosure link and the previous revision tag (v3.3.2).SummaryDifference0.8%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision entries were updated to v3.3.2 and v3.2.0 was removed, reflecting internal version control rather than substantive changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange Detected- Removed the government funding status notice banner from the page; core study content, eligibility criteria, and results information remain unchanged.SummaryDifference0.4%

- Check60 days agoChange DetectedMinor UI/formatting adjustments were made to the Study Details page without altering core study information such as eligibility criteria, primary outcomes, or enrollment status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check88 days agoChange DetectedSummary of changes: updated operating-status notice and version bump from v3.1.0 to v3.2.0, with links to official status pages.SummaryDifference2%

- Check95 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0. No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in Refractory Metastatic Colorectal Cancer Clinical Trial page.